1354355-86-4

Basic information

• Product Name: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid
• Synonyms: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid
• CAS NO: 1354355-86-4
• Molecular Weight: 307.349
• Mol File: 1354355-86-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid(1354355-86-4)
• EPA Substance Registry System: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid(1354355-86-4)

Safety Data

• Hazardous Substances Data: 1354355-86-4(Hazardous Substances Data)

Upstream product

• 335254-97-2 tert-butyl 2-nitro-4-(pyridin-2-yl)phenylcarbamate 
• 855738-60-2 tert-butyl 2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate 
• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 
• 1354355-85-3 tert-butyl 4-(6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 29682-15-3 methyl 5-bromopicolinate 

Relevant articles and documents

A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF

The present invention relates to a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof, and specifically provides a compound of formula (I), or an isotopic compound thereof, or an optical isomer thereof, or a tautomer thereof, or a pharmacologically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, wherein ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform the targeted degradation on androgen receptors in prostate cancer cells, and suppress the proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in the preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating the related diseases regulated by the androgen receptors.

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.